The hepatocellular expression of a carbohydrate antigen 'sialyl Lewis X' in chronic hepatitis. A novel histological marker for active hepatic necroinflammation. 1990

Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
First Department of Internal Medicine, Okayama University Medical School, Japan.

The hepatocellular expression of the carbohydrate antigen sialyl monomeric Lewis X (SMLex) and sialyl oligomeric Lewis X(SOLex) in chronic hepatitis was examined using specific monoclonal antibodies. Both of these sialyl Lewis X (SLex) antigens were membranously expressed in chronic hepatitis in spite of their absence in normal liver. Although SMLex was detected in mild hepatic inflammation, the expression of SOLex was associated only with moderate to severe necroinflammation. Hepatocellular expression of these antigens increased significantly as histological diagnosis advanced. Chronological observation also showed the change of SLex expression according to the histological change. The present observations suggest that hepatocellular SLex is a novel histological marker with a close correlation to the severity of necroinflammation in chronic hepatitis.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006017 Glycolipids Any compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such as an acylglycerol (see GLYCERIDES), a sphingoid, a ceramide (CERAMIDES) (N-acylsphingoid) or a prenyl phosphate. (From IUPAC's webpage) Glycolipid
D006505 Hepatitis INFLAMMATION of the LIVER. Hepatitides
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016256 Lewis X Antigen A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, Lewis X antigen is a stage-specific embryonic antigen. Antigens, CD15,CD15 Antigens,Le(X) Antigen,Leu-M1 Antigens,Lewis X Related Antigens,SSEA-1,SSEA-1 Determinant,Stage-Specific Embryonic Antigen-1,3 alpha-Fucosyl-N-Acetyl Lactosamine,CD15 Antigen,Galbeta(1-4)Fucalpha(1-3)GlcNAc,Hapten X,Lewis X Hapten,SSEA 1,3 alpha Fucosyl N Acetyl Lactosamine,Antigen, Lewis X,Embryonic Antigen-1, Stage-Specific,Leu M1 Antigens,SSEA 1 Determinant,Stage Specific Embryonic Antigen 1,X Antigen, Lewis,X Hapten, Lewis

Related Publications

Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
January 2021, Frontiers in immunology,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
April 1994, Cancer,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
January 1995, Hepato-gastroenterology,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
April 2012, Histology and histopathology,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
April 1997, Diseases of the colon and rectum,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
November 1993, Journal of hepatology,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
February 1996, Nihon Geka Gakkai zasshi,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
October 1993, Cellular immunology,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
January 2002, Hepato-gastroenterology,
Y Okada, and R Usumoto, and M Muguruma, and T Shimoe, and T Sunayama, and G Yamada, and K Yamamoto, and T Yamabuki, and T Tsuji
October 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie,
Copied contents to your clipboard!